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Background
Allergic rhinitis (AR) is the most common chronic 
disease worldwide. Evidence-based guidelines have 
improved knowledge on rhinitis and made a significant 
impact on AR management. However, many patients 
remain inadequately controlled and the costs for society 
are enormous, in particular due to the major impact of 
AR on school and work productivity [1, 2]. Unmet needs 
have identified clearly many gaps. These include (1) sub-
optimal rhinitis and asthma control due to medical, cul-
tural and social barriers [3, 4], (2) poor understanding 
of endotypes [5], better characterization of phenotypes 
and multimorbidities [6], better understanding of gen-
der differences [7], (3) assessment of sentinel networks 
in care pathways for allergen and pollutants exposures, 
using symptom variation [8], (4) lack of stratification of 
patients for optimized care pathways [9] and (5) lack of 
multidisciplinary teams within integrated care pathways, 
endorsing innovation in real life clinical trials [8] and 
encouraging patient empowerment [10, 11].
Mobile health (mHealth) is the use of information and 
communication technology (ICT) for health services and 
information transfer [12]. mHealth, including apps run-
ning on consumer smart devices (i.e., smartphones and 
tablets), is becoming increasingly popular and has the 
potential to profoundly impact on healthcare [13]. Novel 
app-based collaborative systems can have an important 
role in gathering information quickly and improving 
coverage and accessibility of prevention and treatment 
[14]. Implementing mHealth innovations may also have 
disruptive consequences [15], so it is important to test 
applicability in each individual situation [16]. A rapid 
growth of the health apps market has been seen with an 
estimated 325,000 health apps available in 2017 for most 
fields of medicine [17]. Benefits and drawbacks have been 
estimated for a number of disease [18]. The application 
of mHealth solutions can support the provision of high 
quality care to patients with AR or asthma, to the satisfac-
tion of both patients and health care professionals, with a 
reduction in both health care utilization and costs [19]. 
Appropriately identifying and representing stakeholders’ 
interests and viewpoints in evaluations of mHealth is a 
critical part of ensuring continued progress and innova-
tion [20]. Patient, caregiver and clinician evaluations and 
recommendations play an important role in the develop-
ment of asthma mHealth tools to support the provision 
of asthma management [21]. Smart devices and inter-
net-based applications are already used in rhinitis and 
asthma and may help to address some unmet needs [22]. 
However, these new tools need to be tested and evaluated 
for acceptability, usability and cost-effectiveness.
Allergic Rhinitis and its Impact on Asthma (ARIA) has 
evolved from an evidence-based guideline using the best 
evidence based approach [1, 23–25] to care pathways 
using mobile technology in AR and asthma multimorbid-
ity [26]. ARIA appears to be close to the patient’s needs 
but real-life data suggest that few patients follow guide-
line recommendations and that they often self-medicate. 
Moreover, patients frequently using OTC medications 
dispensed in pharmacies [27]. Shared decision making 
(SDM) centered around the patient for self-management 
should be used more often.
Mobile Airways Sentinel networK (MASK), the Phase 
3 ARIA initiative, has been initiated to reduce the global 
burden of rhinitis and asthma multimorbidity, giving the 
patient and the health care professional simple tools to 
better prevent and manage respiratory allergic diseases. 
More specifically, MASK is focusing on (1) understand-
ing the disease mechanisms and the effects of air pollu-
tion in allergic diseases and asthma, (2) better appraising 
the burden incurred by medical needs and indirect costs, 
(3) the implementation of multi-sectoral care pathways 
integrating self-care, air pollution and patient’s literacy, 
using emerging technologies with real world data using 
the AIRWAYS ICPs algorithm [28], (4) proposing indi-
vidualized and predictive medicine in rhinitis and asthma 
multimorbidity, (5) proposing the basis for a sentinel 
network at the global level for pollution and allergy and 
(6) assessing the societal implications of exposure to air 
pollution and allergens and its consequences on health 
inequalities globally.
The freely available MASK app (the Allergy Diary, 
Android and iOS) [26] is combined with an inter-oper-
able tablet for physicians and other health care profes-
sionals (HCPs [29]), using the same extremely simple 
colloquial language to manage AR (Visual Analogue 
Scale: VAS) [30, 31]. It is being combined with data on 
allergen and pollution exposure (POLLAR).
MASK will be scaled up using the EU EIP on AHA 
strategy [32]. Phase 4 is starting in 2018 and will focus 
on “change management”. MASK is supported by several 
EU grants and is a WHO GARD (Global Alliance against 
Chronic Respiratory Diseases) research demonstration 
project (Table 1).
Methods
Users
The Allergy Diary is used by people who searched the 
internet, Apple App store, Google Play or in any other 
way. The pages of the App are on the Euforea-ARIA web-
site (www.eufor ea.eu/about -us/aria.html). A few users 
were clinic patients to whom the app was recommended 
by their physicians. Users were not requested to com-
plete the diary for a minimum number of days. However, 
due to anonymization of data, no specific information on 
the route of access to the app could be gathered [33, 34].
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The first question of the App is “I have allergic rhini-
tis”: Yes/No. We tested the sensitivity and specificity of 
this question [33]. 93.4% users with a positive answer had 
nasal symptoms versus 12.1% of users with a negative 
answer. In the first two versions of the App, allergy was 
not considered in the user’s questionnaire and AR cannot 
be differentiated from chronic rhinosinusitis. It is now 
included in the third version of the App (June 2018) and 
we will be able to answer more appropriately to this ques-
tion in the next study. The results of the pilot study were 
confirmed in over 9000 users.
Settings
MASK is available in 23 countries and 16 languages. To 
date (01-09-2018) the app has been used by over 24,000 
people.
Ethics and privacy of data
The Allergy Diary is CE1 registered. The terms of use 
were translated into all languages and customized by law-
yers according to the legislation of each country, allow-
ing the use of the results for research and commercial 
purposes. The example of the UK terms of use have been 
provided in a previous paper [33].
Geolocation
EU data protection rules have changed since the imple-
mentation of the General Data Protection Regulation 
(Art. 4 para. 1 no. 1 GDPR) [35]. Data anonymization is 
a method of sanitization for privacy. Anonymization ren-
ders personal data “in such a manner that the data sub-
ject is not or no longer identifiable” [36]. The European 
Commission’s Article 29 Working Party (WP29) stated 
already in 2014 with regards to the Directive 95/46/EC 
[37] that geolocation information is not only personal 
data but also to be considered as an identifier itself [38, 
39]. Processing personal data by means of an app, like e.g. 
App Diary, besides Directive 95/46/EC [37] also Directive 
2002/58/EC [40] as amended by Directive 2009/136/EC 
[41] applies.
Geolocation was studied for all people who used the 
Allergy Diary App from December 2015 to November 
2017 and who reported medical outcomes. In contradis-
tinction to noise addition (randomization), k-anonymity 
[42, 43] is an acceptable method for the anonymization of 
MASK data (generalization) [44] and results can be used 
for other databases.
Privacy assessment impact
Privacy impact assessments (PIAs), also known as data 
protection impact assessments (DPIAs) in EU law, is 
required by GDPR (Article 35 Working Party (WP35). 
PIA is a systematic process to assess privacy risks to 
individuals in the collection, use, and disclosure of their 
personal data. The GDPR introduced PIAs to identify 
high risks to the privacy rights of individuals when pro-
cessing their personal data. The assessment shall con-
tain at least:
1. a systematic description of the envisaged process-
ing operations and the purposes of the processing, 
including, where applicable, the legitimate interest 
pursued by the controller;
2. an assessment of the necessity and proportionality of 
the processing operations in relation to the purposes;
3. an assessment of the risks to the rights and freedoms 
of data subjects and
4. the measures envisaged to address the risks, includ-
ing safeguards, security measures and mechanisms to 
ensure the protection of personal data and to dem-
Table 1 European Union and World Health Organization links of ARIA and MASK
Date WHO EU
ARIA 1999 Workshop WHO HQ
2003–2013 CC rhinitis and asthma Montpellier
2012– GARD demonstration project WHO HQ
2004–2010 GA2LEN FP6
2011–2015 MeDALL FP7
MASK 2014– MACVIA‑LR DG Santé‑CNECT
2014– GARD demonstration project WHO HQ
2014– EIP on AHA B3 DG Santé‑CNECT
2015–2016 SPAL Structural and develop‑
ment funds
2015–2017 Sunfrail
2017– Twinning DG Santé‑CNECT
2018– POLLAR EIT Health
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onstrate compliance with this Regulation taking into 
account the rights and legitimate interests of data 
subjects and other persons concerned.
When these risks are identified, the GDPR expects that 
an organization formulates measures to address these 
risks. Those measures may take the form of technical 
controls such as encryption or anonymization of data.
The PIA analysis is a self-declarative analysis. In France, 
the local GDPR representative (Commission Informa-
tique et Liberté, CNIL) has provided a software to guide 
the reflexion around security of personal data and the 
exposure risks in case of security fails. This software has 
been used to assess all the risks to be considered through 
the app uses. The conclusion was that is “negligeable”.
The field is moving very fast. In France, June, 10 2018, 
the modified law “LIL” (Loi Informatique et Liberté, 
2018-493, https ://www.cnil.fr/fr/loi-78-17-du-6-janvi 
er-1978-modifi ee) was enacted with a special focus on 
health-related personal data. Even if the articulation of 
GDPR and LIL is still unclear, we can anticipate that the 
app use will remain risk free.
Allergy Diary
The app collects information on AR and asthma symp-
toms experienced (nasal and ocular) and on disease type 
(intermittent/persistent) [33] (Table 3). Anonymized and 
geolocalized users assess daily how symptoms impact 
their control and AR treatment using the touchscreen 
functionality on their smart phone to click on five con-
secutive VAS (i.e. general, nasal and ocular symptoms, 
asthma and work) (Table 2; Fig. 1). Users input their daily 
medications using a scroll list that contains all coun-
try-specific OTC and prescribed medications available 
(Fig.  2). The list populated using IMS data and revised 
by country experts is continuously revised by country 
experts.  
There is a high degree of correlation between these 
VAS measurements. The example of VAS global meas-
ured and VAS nose is presented in Fig. 2.
Outcomes
Five VAS measurements [VAS-global measured, VAS-
nose, VAS-eye, VAS-asthma and VAS-work (Table  4)] 
and a calculated VAS-global score (VAS-nasal + VAS-
ocular divided by 2) were assessed [34]. VAS levels range 
from zero (not at all bothersome) to 100 (very bother-
some). Independency of VAS questions was previously 
confirmed using the Bland and Altman regression analy-
sis [34, 45].
Transfer of personal data from the App to a print
Patients cannot give access to their electronic data to a 
HCP due to privacy policies. However, they can eas-
ily print the daily control of their disease and the medi-
cations that they filled in the Allergy Diary as follows 
(Fig. 3).
Additional questionnaires
MASK also includes EQ-5D (EuroQuol) [46–48], Work 
Productivity and Activity Impairment Allergic Specific 
(WPAI-AS) [49] and Control of AR and Asthma Test 
(CARAT) [50–53]. The Epworth Sleepiness Question-
naire [54, 55] is included (June 2018).
Medications
A scroll list is available for all OTC and prescribed 
medications of the 23 countries. The International Non-
proprietary Names classification was used for drug 
nomenclature [56]. 85 INNs and 505 medications were 
identified (Fig. 1).
Adherence to treatment
Globally, non-adherence to medications is a major 
obstacle to the effective delivery of health care. Many 
mobile phone apps are available to support people 
to take their medications and to improve medication 
adherence [57, 58]. However, a recent meta-analysis 
found that the majority did not have many of the desir-
able features and were of low quality [57]. However, 
it is unknown how people use apps, what is consid-
ered adherent or non-adherent in terms of app usage, 
or whether adherence with an app in anyway reflects 
adherence with medication or control.
In MASK, we did not use adherence questionnaires 
but first attempted to assess short-term adherence and 
then to address the long-term issues. [59].
Digitalized ARIA symptom‑medication score
Symptom-medication scores are needed to assess the 
control of allergic diseases. They are currently being 
Table 2 Questions on symptoms and impact of symptoms 
(from Bousquet et al. [33])
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developed for MASK and are being compared with 
existing ones [60].
MASK algorithm and clinical decision support system
Clinical decision support systems (CDSS) are software 
algorithms that advise health care providers on the 
diagnosis and management of patients based on the 
interaction of patient data and medical information, 
such as prescribed drugs. CDSS should be based on the 
best evidence and algorithms to aid patients and health 
care professionals to jointly determine the treatment 
and its step-up or step-down strategy for an optimal 
disease control.
The selection of pharmacotherapy for AR patients 
depends on several factors, including age, prominent 
symptoms, symptom severity, AR control, patient 
preferences and cost. Allergen exposure, pollution 
and resulting symptoms vary, needing treatment 
Fig. 1 Allergy Diary screens relating to Visual Analogue Scale and medications (from Bousquet et al. [26])
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adjustment. In AR, The MASK CDSS is incorporated 
into an interoperable tablet [29] for HCPs (ARIA 
Allergy Diary Companion) [10, 26]. This is based on an 
algorithm to aid clinicians to select pharmacotherapy 
for AR patients and to stratify their disease severity [26] 
(Fig. 4). It uses a simple step-up/step-down individual-
ized approach to AR pharmacotherapy and may hold 
the potential for optimal control of symptoms, while 
minimizing side-effects and costs. However, its use var-
ies depending on the availability of medications in the 
different countries and on resources. The algorithm is 
now digitalized and available in English (Fig. 5).
MASK follows the CHRODIS criteria of “Good 
Practice”
The European Commission is co-funding a large col-
laborative project named JA-CHRODIS in the context 
of the 2nd EU Health Programme 2008–2013 [61]. JA-
CHRODIS has developed a check-list of 27 items for the 
evaluation of Good Practices (GP) (http://chrod is.eu/
our-work/04-knowl edge-platf orm/). According to the 
JA-CHRODIS, a Good Practice has been proven to work 
well and produce good results, and is therefore recom-
mended as a model to be scaled up. The JA-CHRODIS 
criteria are grouped into nine categories:
• Equity.
• Practice.
• Ethical considerations.
• Evaluation.
• Empowerment and participation.
• Target population.
• Sustainability.
• Governance.
• Scalability
As part of SUNFRAIL, MASK tested the 27 item cri-
teria of CHRODIS and was found to be an example of 
Good Practice [62].
Pilot study of mobile phone technology in AR
A pilot study in 3260 users found that Allergy Diary users 
were able to properly provide baseline simple phenotypic 
characteristics. Troublesome symptoms were found mainly 
in the users with the largest number of symptoms. Around 
50% of users with troublesome rhinitis and/or ocular 
symptoms suffered work impairment. Sleep was impaired 
by troublesome symptoms and nasal obstruction (Fig.  6). 
results suggest novel concepts and research questions in 
AR that may not be identified using classical methods [33].
Fig. 2 Correlation between Visual Analog Scale (VAS) global measured and nasal symptoms (VAS nose) (unpublished)
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Validation of the MASK Visual Analogue Scale 
on cell phones
VAS included in the Allergy Diary was found to be a vali-
dated tool to assess control in AR patients following COS-
MIN guidelines [63] in 1225 users and 14,612 days: internal 
consistency (Cronbach’s α-coefficient > 0.84 and test–
retest > 0.7), reliability (intra-class correlation coefficients), 
sensitivity and acceptability [64]. In addition, e-VAS had 
a good reproducibility when users (n = 521) answered the 
e-VAS twice in less than 3 h.
Transfer of innovation of AR and asthma 
multimorbidity in the elderly: Reference Site 
Twinning (EIP on AHA)
The EIP on AHA includes 74 Reference Sites. The aim 
of this TWINNING was to transfer innovation from 
the MASK App to other reference sites. The phenotypic 
characteristics of rhinitis and asthma multimorbidity 
in adults and the elderly are compared using validated 
mHealth tools (i.e. the Allergy Diary and CARAT) 
in 23 Reference Sites or regions across Europe and 
Argentina, Australia, Brazil and Mexico [46]. This will 
improve understanding, assessment of burden, diagno-
sis and management of rhinitis in the elderly by com-
parison with an adult population. The pilot study has 
been completed in Germany and the project is fully 
operative using two protocols (Table 3).
Results
Work productivity
AR impairs social life, work and school productivity. 
Indirect costs associated with lost work productivity 
are the principal contributor to the total AR costs and 
result mainly from impaired work performance by pres-
enteeism [2]. The severity of AR symptoms was the most 
consistent disease-related factor associated with impact 
of AR on work productivity, although ocular symptoms 
and sleep disturbances may independently affect work 
Fig. 3 Transfer of patient information on a computer and printed information (from Bousquet et al. [46]
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productivity. Overall, the pharmacologic treatment of AR 
showed a beneficial effect on work productivity.
A cross-sectional study using Allergy diary in 
1136 users (5659  days) assessed the impact on work 
productivity of uncontrolled AR assessed by VAS [34]. 
In users with uncontrolled rhinitis (VAS global meas-
ured ≥ 50), approximately 90% had some work impair-
ment and over 50% had severe work impairment 
Fig. 4 Clinical decision support systems consensus for allergic rhinitis (from Bousquet et al. [28])
Fig. 5 CDSS digitalization (submitted)
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(VAS-work ≥ 50). There was a significant correla-
tion between VAS-global calculated and VAS-work 
(Rho = 0.83, p < 0.00001, Spearman rank test). The study 
has been extended to almost 17,000  days and similar 
results were observed (Fig. 7).
The baseline study found that bothersome symptoms, 
nasal obstruction and ocular symptoms were involved in 
work productivity impact [33] (Fig. 8).
The Allergy Diary includes the WPAI:AS in six EU 
countries. All consecutive users who completed the 
VAS-work from June 1 to July 31, 2016 were included 
in the study [66]. A highly significant correlation was 
found between Questions 4 (impairment of work) and 9 
(impairment of activities) in 698 users (Rho = 0.85).
All these studies combine to confirm the impact of 
uncontrolled AR on work productivity.
Novel phenotypes of allergic diseases
Multimorbidity in allergic airway diseases is well known 
[6], but no data exist regarding the daily dynamics of 
symptoms. The Allergy Diary assessed the presence 
and control of daily allergic multimorbidity (asthma, 
conjunctivitis, rhinitis) and its impact on work produc-
tivity in 4025 users and 32,585  days monitored in 19 
countries from May 25, 2015 to May 26, 2016. VAS lev-
els < 20/100 were categorized as “Low” burden and VAS 
levels ≥ 50/100 as “High” burden. VAS global measured 
levels assessing the global control of the allergic disease 
were significantly associated with daily allergic multi-
morbidity. Eight hypothesis-driven patterns were defined 
based on “Low” and “High” VAS levels. There were < 0.2% 
days of Rhinitis Low and Asthma High or Conjunctivi-
tis High patterns. There were 5.9% days with a Rhinitis 
High—Asthma Low pattern. There were 1.7% days with 
a Rhinitis High—Asthma High—Conjunctivitis Low pat-
tern. A novel Rhinitis High—Asthma High—Conjunc-
tivitis High pattern was identified in 2.9% days and had 
the greatest impact on uncontrolled VAS global meas-
ured and impaired work productivity (Fig. 9). The mobile 
technology enabled investigation in a novel approach of 
the intra-individual variability of allergic multimorbidity 
using days. It identified an unrecognized extreme pattern 
of uncontrolled multimorbidity [59]. 
Treatment of allergic rhinitis using mobile technology 
with real world data
Large observational implementation studies are needed 
to triangulate the findings from randomized control tri-
als (RCTs) as they reflect “real world” everyday practice. 
We attempted to provide additional and complemen-
tary insights into the real-life AR treatment using mobile 
technology. The Allergy Diary was filled in by 2871 users 
Fig. 6 Impact of allergic rhinitis depending on the number of 
symptoms (from Bousquet et al. [33])
Table 3 Twinning protocols (from Bousquet et al., [65])
Protocol 1 Protocol 2
Short version Long version
Allergy Diary + +
Equation 5D Optional +
Physician’s questionnaire +
Ethics committee Not needed Needed (obtained in some Reference Sites)
Inform consent Terms of Reference on App From with patient’s signature
Recruitment Any user
Persons attending clinic visits can be included
Persons attending clinic visits included with a physician’s 
diagnosis of allergic disease and allergen sensitization (IgE 
and/or skin tests)
Physician’s questionnaire +
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Fig. 7 Correlation between VAS work and VAS global measured, nose, eye and asthma (Bousquet unpublished)
Fig. 8 Impact of symptoms on work, school and daily activities (from Bousquet et al. [33])
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who reported 17,091  days of VAS in 2015 and 2016. 
Medications were reported for 9634  days. The assess-
ment of days appeared to be more informative than the 
course of the treatment as, in real life, patients rarely use 
treatment on a daily basis; rather, they appear to increase 
treatment use with the loss of symptom control and 
to stop it when symptoms disappear. The Allergy Diary 
allowed the differentiation between treatments within or 
between classes (intranasal corticosteroid use containing 
medications and oral H1-antihistamines). The control of 
days differed between no (best control), single or multi-
ple treatments (worst control) (Fig.  10). The study con-
firms the usefulness of the Allergy Diary in accessing and 
assessing everyday use and practice in AR [59].
Adherence to medications was studied in almost 7000 
users reporting medications. 1770 users reported over 
Fig. 9 VAS levels in severe rhinitis depending on multimorbidity (from Bousquet et al. [60])
Fig. 10 Treatments received in MAS (from Bousquet et al. [59])
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7  days of VAS between January 1, 2016 and August 
31, 2016 and a major lack of adherence to treatment 
was observed for all medications (Menditto et  al., in 
preparation).
MASK in the pharmacy
Multidisciplinary integrated care is necessary to reduce 
the burden of chronic diseases. A significant proportion 
of patients with AR self-manage their condition and often 
the pharmacist is the first HCP that a person with nasal 
symptoms contacts [66, 67]. Pharmacists are trusted in 
the community and are easily accessible. As such, phar-
macists are an important part of the multidisciplinary 
healthcare team, acting at different steps of rhinitis care 
pathways.
Pharmacists are important in many areas of interven-
tion in AR:
• Recognizing (identification).
• Risk assessment/stratification.
• OTC treatment.
• Manage refils.
• Patient education.
• Referral to a physician.
• Administration of topical treatment technique and 
adherence to treatment.
Simple algorithms and tools are essential in the routine 
implementation of these steps. A first approach was 
made by ARIA in the pharmacy [68] and is currently 
being updated using MASK.
POLLAR (Impact of air POLLution on Asthma 
and Rhinitis)
AR and asthma are impacted by allergens and air pollu-
tion. However, interactions between air pollution, sleep 
[55, 69] and allergic diseases are insufficiently under-
stood. POLLAR aims at combining emerging technolo-
gies [search engine TLR2 (technology readiness level); 
pollution sampler TLR6, App TLR9] with machine learn-
ing to (1) understand effects of air pollution in AR and 
its impact on sleep, work, asthma, (2) propose novel care 
pathways integrating pollution and patient’s literacy, 
(3) study sleep, (4) improve work productivity, (5) pro-
pose the basis for a sentinel network at the EU level for 
pollution and allergy and (6) assess the societal implica-
tions of the interaction.
POLLAR will use the freely existing application for AR 
monitoring (Allergy Diary, 14,000 users, TLR8) com-
bined with a new tool allowing queries on allergen and 
pollen (TLR2) and existing pollution data. Machine 
learning will be used to assess the relationship between 
air pollution and AR comparing polluted and non-pol-
luted areas in 6 EU countries. Data generated in 2018 
will be confirmed in 2019 and extended by the individ-
ual assessment of pollution  (Canarin®, portable sensor, 
TLR6) in AR and sleep apnea patients used as a control 
group having impaired sleep. The geographic information 
system GIS will map the results.
Google Trends (GT) searches trends of specific que-
ries in Google and reflects the real-life epidemiology of 
AR. We compared GT terms related to allergy and rhi-
nitis in all European Union countries, Norway and Swit-
zerland from January 1, 2011 to December, 20 2016. An 
annual and clear seasonality of queries was found in most 
countries but the terms ‘hay fever’, ‘allergy’ and ‘pollen’—
show cultural differences [70]. Using longitudinal data in 
different countries and multiple terms, we identified an 
awareness-related spike of searches (December 2016) 
[70]. In asthma, GTs can identify spikes of mortality as 
was found in Australia and Kuwait in 2016. However, the 
usual peaks of asthma during allergen exposure or virus 
infections cannot be easily monitored [71].
Global applicability of MASK and POLLAR, 
and their benefits
Although MASK has been devised to optimize care path-
ways in rhinitis and asthma multimorbidity, its applica-
bility is far more extensive (Table 4).
For MASK, several steps have been achieved.
Conclusion
MASK is a novel approach to obtain real-life data con-
cerning rhinitis and asthma multimorbidity and to help 
patients and physicians for a better SDM. It can be used 
for multiple purposes in a friendly manner in order to 
improve the control of allergic diseases in a cost-effective 
approach.
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Cycle; MACVIA‑LR: contre les MAladies Chroniques pour un VIeillissement Actif 
Table 4 Global applicability of MASK
Applicability MASK
Clinical practice Physicians will be able to read the files of the patients in order to
 Optimize treatment for the patient and, in particular, the current or the next pollen season
 Assess and increase the adherence to treatment
 Help for shared decision making
 Prescribe allergen immunotherapy (AIT) more rapidly when the patient is not controlled despite 
optimal pharmacologic treatment
 Determine the efficacy of AIT in patients
 The Allergy Diary is an essential tool to provide personalized medicine in AR and asthma
Change management The first results of MASK indicate that many patients are uncontrolled and non‑adherent to treatment
Moreover, they appear to use their medications as needed and not as a regular basis as prescribed
Change management is needed
Patient empowerment Better understanding of the symptoms
Sentinel network linking aerobiology data and control
Improved adherence
Self‑management
Patient empowerment
Messages sent by the App
Clinical trials For RCTs, it is essential to have clarity on definitions, and relevant tools. The Allergy Diary allows
 To better stratify the patients needing AIT
 To assess the efficacy of AIT during the trial
 To assess the efficacy when AIT is stopped
Observational studies are of key importance to confirm RCTs and bring new hypotheses for the treat‑
ment of AR and asthma
Registration and reimbursement of medicines Controlled trials designed with a uniform approach will be more easily evaluated by the Health 
Technology Assessment agencies (such as NICE) for reimbursement. The Allergy Diary uses EQ‑5D, a 
validated measure of utility
Better understanding of direct and indirect costs
Controlled trials designed with a uniform approach will help to synchronize data from real‑life world 
regarding clinical effects and safety/tolerability of new drugs (post‑marketing pharmacovigilance
Research on mechanisms and genetics A uniform definition and a collaborative approach to epidemiological, genetic and mechanistic 
research are important and will be enhanced by the stratification of patients using the Allergy Diary
Different levels of phenotype characterization (granularity) can be applied to assess phenotypic char‑
acterization in old age subjects
Epidemiology In epidemiologic population studies, standardized definitions and tools are fundamental. The Allergy 
Diary allows novel approaches combining classical cross‑sectional and longitudinal studies with real 
life studies in large populations
Employers AR and asthma represent a major burden for the employers, and the estimated annual costs in the EU 
range from 30 to 60 B€. Better control of the disease was shown to reduce costs. The Allergy Diary has 
the potential to improve the control of allergic diseases and to significantly improve work productiv‑
ity at the EU level
Public health planning For public health purposes, a perfect patient characterization in real life is needed to identify the 
prevalence, burden and costs incurred by patients in order to improve quality of care and optimize 
health care planning and policies
Reduction of inequities Inequities still exist in the EU for allergic diseases prevalence and burden (not only sex/gender inequi‑
ties). POLLAR will attempt to understand them and to propose policies and health promotion 
strategies
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(Fighting chronic diseases for AHA); MASK: Mobile Airways Sentinel networK; 
MeDALL: Mechanisms of the Development of ALLergy (FP7); mHealth: mobile 
health; NCD: non‑communicable disease; OTC: over the counter; PIA: privacy 
Impact Assessment; POLLAR: Impact of air POLLution on Asthma and Rhinitis; 
QOL: quality of life; SCUAD: severe chronic upper airway disease; TRL: technol‑
ogy readiness level; TWINNING: transfer of innovation of mobile technology; 
VAS: Visual Analogue Scale; WHO: World Health Organization; WPAI‑AS: Work 
Productivity and Activity Questionnaire.
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